Nuclear Factor Kappa B: Important Transcription Factor and Therapeutic Target
Jang-Ik Lee PharmD
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Search for more papers by this authorCorresponding Author
Dr. Gilbert J. Burckart PharmD, FCP, FCCP
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
721 Salk Hall, University of Pittsburgh, Pittsburgh, PA 15261.Search for more papers by this authorJang-Ik Lee PharmD
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
Search for more papers by this authorCorresponding Author
Dr. Gilbert J. Burckart PharmD, FCP, FCCP
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
721 Salk Hall, University of Pittsburgh, Pittsburgh, PA 15261.Search for more papers by this authorAbstract
Nuclear factor kappa B (NF-κB) is an ubiquitous rapid response transcription factor in cells involved in immune and inflammatory reactions, and exerts its effect by expressing cytokines, chemokines, cell adhesion molecules, growth factors, and immunoreceptors. In this manner, NF-κB contributes to immunologically mediated diseases such as allograft rejection, rheumatoid arthritis, and bronchial asthma. The prototypic inducible form of NF-κB is a heterodimer composed of NF-kB1 and RelA, which both belong to the NF-κB/Rel family of proteins. Inactive NF-κB is present in the cytoplasm complexed with an inhibitory protein, IκB. NF-κB is activated by a number of incoming signals from the cell surface. Released from IκB inhibition, NF-κB translocates into the nucleus and binds to the κB motif of the target gene. The NF-κB activation process can be inhibited by pharmacologic agents at each activation step. Glucocorticoids inhibit NF-κB by directly associating with NF-κB or by upregulating IκB expression. Cyclosporin and tacrolimus prevent NF-κB activation by inhibiting the action of calcineurin, a phosphatase that indirectly induces IκB degradation. Deoxyspergualin inhibits NF-κB by blocking its nuclear translocation. Aspirin and salicylates inhibit upstream events inducing IκB phosphorylation. Tepoxalin and antioxidants inhibit NF-κB activation by influencing the redox state of the cell. Further research is required to develop more specific inhibitors to treat diseases mediated by NF-κB.
References
- 1 Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705–716.
- 2 Thanos D, Maniatis T: NF-κB: a lesson in family values. Cell 1995; 80: 529–532.
- 3 Blackwell TS, Christman JW: The role of nuclear factor-IκB in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3–9.
- 4 Baldwin AS: The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649–681.
- 5 Wulczyn FG, Krappmann D, Scheidereit C: The NF-κB/Rel and IκB gene families: mediators of immune response and inflammation. J Mol Med 1996; 74: 749–769.
- 6 Baeuerle PA, Henkel T: Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994; 12: 141–179.
- 7 Miyamoto S, Verma IM: Rel/NF-κB/IκB story. Adv Cancer Res 1995; 66: 255–292.
- 8 Schmitz ML, Baeuerle PA: Multi-step activation of NF-κB/Rel transcriptional factors. Immunobiology 1995; 193: 116–127.
- 9 Liou HC, Sha WC, Scott ML, Baltimore D: Sequential induction of NF-κB/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994; 14: 5349–5359.
- 10 Matthews JR, Hay RT: Regulation of the DNA binding activity of NF-κB. Int J Biochem Cell Biol 1995; 27: 865–879.
- 11 Akira S, Kishimoto T: NF-IL6 and NF-κB in cytokine gene regulation. Adv Immunol 1997; 65: 1–46.
- 12 Schreck R, Rieber P, Baeuerle P: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J 1991; 10: 2247–2258.
- 13 Baeuerle PA, Baltimore D: NF-κB: ten years after. Cell 1996; 87: 13–20.
- 14 Janosch P, Schellerer M, Seitz T, Reim P, Eulitz M, Brielmeier M: Characterization of IκB kinases: IκBα is not phosphorylated by Raf-1 or protein kinase C isoenzymes, but is a casein kinase II substrate. J Biol Chem 1996; 271: 13868–13874.
- 15 Chiao PJ, Miyamoto S, Verma IM: Autoregulation of IκBα: activity. Proc Natl Acad Sci USA 1994; 91: 28–32.
- 16 Kopp EB, Ghosh S: NF-κB and Rel proteins in innate immunity. Adv Immunol 1995; 58: 1–17.
- 17 Beg A, Sha W, Bronson R, Ghosh S, Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995; 376: 167–170.
- 18 Sharma HW, Narayanan R: The NF-κB transcription factor in oncogenesis. Anticancer Res 1996; 16: 589–596.
- 19 Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ: Activation of HIV gene expression during monocyte differentiation by induction of NF-κB. Nature 1989; 339: 70–73.
- 20 Baeuerle PA, Baichwal VR: NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997; 65: 111–137.
- 21 Los M, Schenk H, Hexel K, Baeuerle PA, Dorge W, Schulze-Osthoff K: IL-2 gene expression and NF-κB activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J 1995; 14: 3731–3740.
- 22 Jain J, Loh C, Rao A: Transcriptional regulation of the IL-2 gene. Curr Opin Immunol 1995; 7: 333–342.
- 23 Köntgen F, Grumont R, Strasser A, Metcalf D, Li R, Gerondakis S: Mice lacking the c-Rel protooncogene exhibit defects in lymphocyte proliferation, humoral immunity, and IL-2 expression. Genes Dev 1995; 9: 1965–1977.
- 24 Chen CC, Manning AM: Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-κB. Agents Actions 1995; 47: 135–141.
- 25 Segars JH, Nagata T, Bours V, Medin JA, Franzoso G, Blanco JCG: Retinoic acid induction of major compatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF-κB (p50-p65) and retinoic acid receptor-β-retinoid X receptor-β heterodimers. Mol Cell Biol 1993; 13: 6157–6169.
- 26 Hemar A, Cereghini S, Cornet V, Israel A, Greene W, Dautry-Varsat A: κB binding proteins are constitutively expressed in an IL-2 autocrine human T cell line. J Immunol 1991; 146: 2409–2416.
- 27 Sha W, Liou HC, Tuomanen E, Baltimore D: Targeted disruption of the p50 subunit of NF-κB leads multifocal defects in immune responses. Cell 1995; 80: 321–330.
- 28 Bach FH, Ferran C, Soares M, Wrighton CJ, Anrather J, Winkler H: Modification of vascular responses in xenotransplantation: inflammation and apoptosis. Nature Med 1997; 3: 944–948.
- 29 Bach FH, Ferran C, Candinas D, Miyatake T, Koyamada N, Mark W: Accommodation of xenografts: expression of protective genes in endothelial and smooth muscle cells. Transplant Proc 1997; 29: 56–58.
- 30 Handel ML, McMorrow LB, Gravallese EM: Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995; 38: 1762–1770.
- 31 Sakurada S, Kato T, Okamoto T: Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 1996; 8: 1483–1493.
- 32 Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall LA: Manipulation of distinct NF-κB proteins alters interleukin-1β-induced human rheumatoid synovial fibroblast prostaglandin E2 formation. J Biol Chem 1996; 271: 31496–31501.
- 33 Barnes PJ: Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996; 154: S21–S27.
- 34 Stacey MA, Sun G, Vassalli G, Marini M, Bellini A, Mattoli S: The allergen Der p1 induces NF-κB activation through interference with IκBα function in asthmatic bronchial epithelial cells. Biochem Biophys Res Commun 1997; 236: 522–526.
- 35 Mukaida N, Ishikawa Y, Ikeda N, Fujioka N, Watanabe S, Kuno K, Matsushima K: Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NF-κB and regulation of cytokine production/action through 2 integrin in vivo. J Leukoc Biol 1996; 59: 145–151.
- 36 Böhrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Bottiger BW: Role of NF-κB in the mortality of sepsis. J Clin Invest 1997; 100: 972–985.
- 37 Neurath MF, Pettersson S, Meyer zum Buschenfelde, Strober W: Local administration of antisense phosphorothiotate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nature Med 1996; 2: 998–1004.
- 38 Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, Abraham E: Nuclear factor-κB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996; 24: 1285–1292.
- 39 Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R: Activated transcription factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715–1722.
- 40 Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kalscnmidt C: Transcription factor NF-κB is activated in primary neurons by amyloid β-peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 2642–2647.
- 41 Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription of NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91: 752–756.
- 42 Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K: Novel mechanism of glucocorticoid-mediated gene repression: nuclear factor-κB is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 1994; 269: 13289–13295.
- 43 Caldenhoven E, Liden J, Wissink, Van de Stolpr A, Raaijmakers J, Koenderman L: Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the anti-inflammatory action of glucocorticoids. Mol Endocrinol 1995; 9: 401–412.
- 44 Auphan N, DiDinato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270: 286–290.
- 45 Kleinert H, Euchenhofer C, Ihrig-Biedert I, Forstermann U: Glucocorticoids inhibit the induction of nitric oxide synthase II by down-regulating cytokine-induced activity of transcription factor nuclear factor-κB. Mol Pharmacol 1996; 49: 15–21.
- 46 Brostjan C, Anrather J, Csizmadia V, Natarajan G, Winkler H: Glucocorticoids inhibit E-selectin expression by targetting NF-κB and not ATF/c-Jun. J Immunol 1997; 158: 3836–3844.
- 47 Cato AC, Wade E: Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 1996; 18: 371–378.
- 48 Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y: The effect of dexamethasone on the expression of activated NF-κB in adjuvant arthritis. Clin Immunol Immunopathol 1997; 83: 173–178.
- 49 Crofford LJ, Wilder RL, Ristimaki AP, Remmers EF, Epps HR, Hla T: Cyclooxygenase-1 and −2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095–1101.
- 50 Crofford LJ, Tan B, McCarthy CJ, Hla T: Involvement of nuclear factor κB in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum 1997; 40: 226–236.
- 51 Didonato JA, Saatcioglu F, Karin M: Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids. Am J Respir Crit Care Med 1996; 154: S11–S15.
- 52 Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS: Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283–286.
- 53 Brostjan C, Anrather J, Csizmadia V, Stroka D, Soares M, Bach FH, Winkler H: Glucocorticoid mediated repression of NF-κB activity in endothelial cells does not involve induction of IκB synthesis. J Biol Chem 1996; 171: 19612–19616.
10.1074/jbc.271.32.19612 Google Scholar
- 54 Adcock IM, Brown CR, Barnes PJ: Tumor necrosis factor α causes retention of activated glucocorticoid receptor within the cytoplasm of A549 cells. Biochem Biophys Res Commun 1996; 225: 545–550.
- 55 Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136–142.
- 56 Franz B, Nordby EC, Bren G, Steffan N, Paya CV, Kinkade RL: Calcineurin acts in synergy with PMA to inactivate IκB/MAD3, an inhibitor of NF-κB. EMBO J 1994; 13: 861–870.
- 57 McCaffrey PG, Kim PK, Valge-Archer VE, Sen R, Rao A: Cyclosporin A sensitivity of the NF-κB site of the IL2Rα promoter in untransformed murine T cells. Nucl Acids Res 1994; 22: 2134–2142.
- 58 Wechsler AS, Gordon MC, Dendorfer U, LeClair KP: Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway. J Immunol 1994; 153: 2515–2523.
- 59 Okamoto S, Mukaida N, Yasumoto K, Rice N, Ishikawa Y, Horiguchi H: The interleukin-8 AP-1 and κB-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. J Biol Chem 1994; 269: 8582–8589.
- 60 Venkataraman L, Burakoff SJ, Sen R: FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J Exp Med 1995; 181: 1091–1099.
- 61 Kunz D, Walker G, Eberhardt W, Nitsch D, Pfeilschifter J: Interleukin 1β-induced expression of nitric oxide synthase in rat renal mesangial cells is suppressed by cyclosporin A. Biochem Biophys Res Commun 1995; 216: 438–446.
- 62 Cockerill GW, Bert AG, Ryan GR, Gamble JR, Vadas MA, Cockerill PN: Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. Blood 1995; 86: 2689–2698.
- 63 Holschermann H, Durfeld F, Maus U, Bierhaus A, Heidinger K, Lohmeyer J: Cyclosporin A inhibits tissue expression in monocytes/macrophages. Blood 1996; 88: 3837–3845.
- 64 Meyer S, Kohler NG, Joly A: Cyclosporin A is an uncompetitive inhibitor of proteosome activity and prevents NF-κB activation. FEBS Lett 1997; 413: 354–358.
- 65 Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A: Cyclosporin A interferes with the inducible degradation of NF-κB inhibitors, but not with the processing of p105/NF-κB1 in T cells. Eur J Immunol 1997; 27: 1601–1609.
- 66 Nadler SG, Eversole ACB, Tepper MA, Cleaveland JS: Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995; 17: 700–703.
- 67 Ramos EL, Nadler SG, Grasela DM, Kelly SL: Deoxyspergualin: mechanism of action and pharmacokinetics. Transplant Proc 1996; 28: 873–875.
- 68 Tepper MA, Nadler SG, Esselstyn J, Sterbenz KG: Deoxyspergualin inhibits light chain expression in 70Z/3 pre-B cells by blocking LPS-induced NF-κB activation. J Immunol 1995; 155: 2427–2436.
- 69 Melnick J, Argon Y: Molecular chaperons and the biosynthesis of antigen receptors. Immunol Today 1995; 16: 243–250.
- 70 Weissmann G: The actions of NSAIDs. Hosp Pract 1991; 26: 60–76.
- 71 Mitchell JA, Akarasereenont P, Thiemmermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693–11697.
- 72 Kopp E, Ghosh S: Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994; 265: 956–959.
- 73 Pierce JW, Read MA, Ding H, Luscinskas Collins T: Salicylates inhibit IκBα phosphorylation, endothelial leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996; 156: 3961–3969.
- 74 Weber C, Erl W, Pietsch A, Weber PC: Aspirin inhibits nuclear factor-κB mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995; 91: 1914–1917.
- 75 Vervoordeldonk MJ, Torra IM, Aarsman AJ, van den Bosch H: Aspirin inhibits expression of the interleukin-1β-inducible group II phospholipase A2. FEBS Lett 1996; 397: 108–112.
- 76 Fung-Leung W, Pope B, Chourmouzis E, Panakos JA, Lau CY: Tepoxalin, a novel immunomodulatory compound, synergizes with CsA in suppression of graft-versus-host reaction and allogeneic skin graft rejection. Transplantation 1995; 60: 362–368.
- 77 Kazmi SMI, Plante RK, Visconti V, Taylor GR, Zhou L, Lau CY: Suppression of NF-κB activation and NF-κB-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J Cell Biochem 1995; 57: 299–310.
- 78 Ritchie DM, Argentieri DC, Aparicio BL, Plante RK, Lau CY, Barbone AG: Cytokine modulating-activity of tepoxalin, a new potential antirheumatic. Int J Immunopharmacol 1995; 17: 805–812.
- 79 Read MA, Neish AS, Luscinskas FW, Palombella VJ, Mantiatis T, Collins T: The proteosome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 2: 493–506.
- 80 Wang P, Wu P, Siegel M, Egan R, Billah M: Interleukin-10 inhibits nuclear NF-κB activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270: 9558–9563.
- 81 May MJ, Ghosh S: Signal transduction through NF-κB. Immunol Today 1998; 19: 80–88.